Anna Fateeva

Ms. Anna Fateeva

Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AFAnna Fateeva
Anna Fateeva
Kevinn EddyKevinn Eddy
Kevinn Eddy
SCSuzie Chen
Suzie Chen
Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs. Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles.

13 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
Kevinn EddyKevinn Eddy
Kevinn Eddy
MEMohamad Naser Eddin
Mohamad Naser Eddin
AFAnna Fateeva
Anna Fateeva
SPStefano Vito Boccadamo Pompili
Stefano Vito Boccadamo Pompili
RSRaj Shah
Raj Shah
SCSuzie Chen
Suzie Chen
Cancer is the second leading cause of death, and incidences are increasing globally. Simply defined, cancer is the uncontrolled proliferation of a cell, and depending on the tissue of origin, the cancer etiology, biology, progression, prognosis, and treatment will differ. Carcinogenesis and its progression are associated with genetic factors that can either be inherited and/or acquired and are classified as an oncogene or tumor suppressor. Many of these genetic factors converge on common signaling pathway(s), such as the MAPK and PI3K/AKT pathways. In this review, we will focus on the metabotropic glutamate receptor (mGluR) family, an upstream protein that transmits extracellular signals into the cell and has been shown to regulate many aspects of tumor development and progression. We explore the involvement of members of this receptor family in various cancers that include breast cancer, colorectal cancer, glioma, kidney cancer, melanoma, oral cancer, osteosarcoma, pancreatic cancer, prostate cancer, and T-cell cancers. Intriguingly, depending on the member, mGluRs can either be classified as oncogenes or tumor suppressors, although in general most act as an oncogene. The extensive work done to elucidate the role of mGluRs in various cancers suggests that it might be a viable strategy to therapeutically target glutamatergic signaling.

8 December 2023 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
AFAnna Fateeva
Anna Fateeva
Kevinn EddyKevinn Eddy
Kevinn Eddy
SCSuzie Chen
Suzie Chen
Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.

29 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
Kevinn EddyKevinn Eddy
Kevinn Eddy
KGKajal Gupta
Kajal Gupta
JPJeffrey C. Pelletier
Jeffrey C. Pelletier
AIAllison L. Isola
Allison L. Isola
CMChristina Marinaro
Christina Marinaro
SCSuzie Chen
Suzie Chen
Mouse models that reflect human disorders provide invaluable tools towards the translation of basic science discoveries to clinical therapies. However, many of these in vivo therapeutic studies are short-term and do not accurately mimic patient conditions. In this study, we utilized a fully immuno-competent, transgenic mouse model, TGS, in which the spontaneous development of metastatic melanoma is driven by the ectopic expression of a normal neuronal receptor, metabotropic glutamate receptor 1 (mGluR1), as a model to assess longitudinal treatment response (up to 8 months) with an inhibitor of glutamatergic signaling, troriluzole, a prodrug of riluzole, plus an antibody against programmed cell death protein-1 (PD-1), an immune-checkpoint inhibitor. Our results reveal a sex-biased treatment response that led to an improved survival in troriluzole and/or anti-PD-1 treated male mice that correlated with differential CD8+ T-cells and CD11b+ myeloid cell populations in the tumor-stromal interface, supporting the notion that this model is a responsive and tractable system for evaluating therapeutic regimens for melanoma in an immuno-competent setting.

28 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
AFAnna Fateeva
Anna Fateeva
SCSuzie Chen
Suzie Chen
Editorial: The role of immunotherapy in melanomas

20 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AFAnna Fateeva
Anna Fateeva
SCSuzie Chen
Suzie Chen
Melanoma only accounts for about 1% of cases in skin cancer, unlike basal cell and/or squamous cell carcinomas; however, it owes its notoriety to being the deadliest type of skin cancer